Benitec Biopharma (BNTC) Receivables (2019 - 2025)

Benitec Biopharma has reported Receivables for 7 years, with the latest figure at $130000.0 in Q4 2025.

• Quarterly Receivables changed N/A year-over-year to $130000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $130000.0 (changed N/A YoY) and the FY2025 annual result came in at $33000.0, down 85.59% from the prior year.
• Receivables grew to $130000.0 in Q4 2025 per BNTC's latest filing, from $7000.0 in the prior quarter.
• Over five years, Receivables peaked at $229000.0 in Q2 2024 and troughed at $3000.0 in Q3 2021.
• A 5-year average of $42000.0 and a median of $25000.0 in 2021 frame the typical range for Receivables.
• The sharpest annual moves came in 2023 and 2025: Receivables jumped 1733.33% in 2023, then slumped 94.34% in 2025.
• Over 5 years, Receivables stood at $5000.0 in 2021, then surged by 1260.0% to $68000.0 in 2022, then slipped by 22.06% to $53000.0 in 2023, then tumbled by 92.45% to $4000.0 in 2024, then surged by 3150.0% to $130000.0 in 2025.
• According to Business Quant data, Receivables over the past three periods registered $130000.0, $7000.0, and $33000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.